文献速递颈动脉与弓上血管

系统性溶栓后因症状性病变行颈动脉干预的并发症

Complications of Carotid Interventions for Symptomatic Lesions after Systemic Thrombolysis.
PubMed 文献 · Ann Vasc Surg · 2024-05-29

本研究基于2007至2019年单机构前瞻性数据库,纳入1139例因症状性病变行颈动脉内膜剥脱术(CEA)或经股动脉颈动脉支架置入术(tfCAS)的患者,其中56例(5%)术前接受系统性溶栓(ST)。倾向评分调整后,ST与围术期出血/重返手术室(OR 0.37,95%CI 0.02-1.63,P=0.309)或卒中(OR 0.62,95%CI 0.16-2.40,P=0.493)风险增加无关。作者认为对已接受ST的患者早期颈动脉干预是安全的,症状性患者应避免延迟。

要点

  • 倾向评分调整后,ST组与非ST组围术期出血/重返手术室风险无显著差异(OR 0.37,95%CI 0.02-1.63,P=0.309)。
  • 调整后ST组与非ST组卒中风险无显著差异(OR 0.62,95%CI 0.16-2.40,P=0.493)。
  • 作者认为对已接受ST的症状性患者早期颈动脉干预是安全的,应避免延迟。

核心结论

  • ST does not convey a higher risk of complications after CEA or tfCAS.
  • After controlling for other factors, patients that received ST had similar rates of local complications and stroke when compared to non-ST patients.
  • Early carotid intervention is safe in patients that have received ST, and delays should be avoided in symptomatic patients given the high risk of recurrent stroke.

研究设计与样本

  • 多专科、机构内、前瞻性维护数据库查询,纳入2007至2019年因症状性病变行CEA或tfCAS的患者。
  • 共纳入1139例患者,其中CEA 949例(82%),tfCAS 190例(17%)。
  • 所有治疗病变均为症状性,其中卒中550例(48%),短暂性脑缺血发作603例(52%)。
  • 56例(5%)患者接受ST;56例中15例同时接受导管为基础的卒中干预。
  • ST给药时间:术前0至1天21例(38%),术前2至6天27例(48%),术前大于6天8例(14%)。

主要发现

  • ST组患者更可能以卒中就诊(93% vs. 45%;P < 0.001)且术前Rankin评分更高。
  • 未调整的出血/重返手术室发生率ST组为3%,非ST组为3%(P = 0.60)。
  • 未调整的卒中发生率ST组为4%,非ST组为3%(P = 0.91)。
  • 未调整的围术期死亡率ST组为5%,非ST组为1%(P = 0.009)。
  • 调整患者因素、术前抗血小板/抗凝及手术因素后,ST与围术期出血/重返手术室风险增加无关(OR 0.37;95%CI 0.02-1.63;P = 0.309),与卒中风险增加无关(OR 0.62;95%CI 0.16-2.40;P = 0.493)。

临床怎么用

  • 作者认为,对已接受ST的患者,早期颈动脉干预是安全的,症状性患者应避免延迟。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Series detailing complications after carotid endarterectomy (CEA) and transfemoral carotid stenting (tfCAS) for patients presenting with neurologic symptoms that are treated with systemic thrombolysis (ST) are sparse. We sought to determine if treatment with ST was associated with a higher rate of post-carotid intervention complications. METHODS: A multispecialty, institutional, prospectively maintained database was queried for symptomatic patients treated with CEA or tfCAS from 2007 to 2019. The primary outcomes of interest were bleeding complications (access/wound complications, hematuria, intracranial hemorrhage) or need for reintervention, stroke, and death. We compared rates of these outcomes between patients who were and were not treated with ST. To adjust for preoperative patient factors and confounding variables, propensity scores for assignment to ST and non-ST were calculated. RESULTS: There were 1,139 patients included (949 [82%] CEA and 190 [17%] tfCAS. All treated lesions were symptomatic (550 [48%] stroke, 603 [52%] transient ischemic attack). Fifty-six patients (5%) were treated with ST. Fifteen of 56 patients also underwent catheter-based intervention for stroke. ST was administered 0 to 1 day preoperatively in 21 (38%) patients, 2 to 6 days preoperatively in 27 (48%) patients, and greater than 6 days preoperatively in 8 (14%) patients. ST patients were more likely to present with stroke (93% vs. 45%; P < 0.001) and have higher preoperative Rankin scores. Unadjusted rate of bleeding/return to operating room was 3% for ST group and 3% for non-ST group (P = 0.60). Unadjusted rate of stroke was 4% for ST group and 3% for the non-ST group (P = 0.91), while perioperative mortality was 5% for ST group and 1% for non-ST group (P = 0.009). After adjusting for patient factors, preoperative antiplatelet/anticoagulation, and operative factors, ST was not associated with an increased odds of perioperative bleeding/return to the operating room (odds ratio 0.37; 95% confidence interval: 0.02-1.63; P = 0.309) or stroke (odds ratio 0.62; 95% confidence interval: 0.16-2.40; P = 0.493). CONCLUSIONS: ST does not convey a higher risk of complications after CEA or tfCAS. After controlling for other factors, patients that received ST had similar rates of local complications and stroke when compared to non-ST patients. Early carotid intervention is safe in patients that have received ST, and delays should be avoided in symptomatic patients given the high risk of recurrent stroke.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Bellomo TR, DeCarlo C, Lella SK, et al. Complications of Carotid Interventions for Symptomatic Lesions after Systemic Thrombolysis. Ann Vasc Surg. 2024. PMID: 38821470. doi:10.1016/j.avsg.2024.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。